INS and metabolic dysfunction-associated steatohepatitis: Higher proportion of fibrosis improvement without worsening of MASH (35% vs. 19% for placebo), and of MASH resolution without worsening fibrosis (22% vs. 13% for placebo)Pruritus in almost one-fourth of the patients, worsened insulin resistance and lipid profile